I agree. Maybe they can salvage the ~30% X4 or dua

I agree. Maybe they can salvage the ~30% X4 or dual tropic patients with their GS-6207 inhibitor or current drugs. I had reduced my GILD holding when I learned of CYDY and was holding a portion still thinking they may license leronlimab, but no longer think that is likely. If someone does IMO it will be a competitor as they seem to confident with their current dominating position and their new CEO is probably not even settled yet.

Please do your own due diligence. All my posts and comments are not to be considered investment advice.